Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 16,401 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Central Nervous System Disorder Clear all

Conditions: Infantile Neuroaxonal Dystrophy
Interventions: RT001; Drug
Lead sponsor: Biojiva LLC; Industry
Eligibility: 18 Months to 10 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: San Francisco, California • Morristown, New Jersey

Conditions: Diffuse Intrinsic Pontine Glioma
Interventions: Tumor Lysate Vaccine, Imiquimod, Radiation therapy; Biological · Drug · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 3 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alzheimer Disease
Interventions: Mediterranean Diet, Study Supplement, Low-fat Diet; Behavioral · Dietary Supplement
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment
Interventions: No Intervention, donanemab; Other · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 23
States / cities: Phoenix, Arizona • Irvine, California • Bradenton, Florida + 19 more

Conditions: Alzheimer's Disease
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more

Conditions: Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions: Placebos for acetaminophen and N-acetylcysteine, APAP 1 gm every 6 hours and N-acetylcysteine placebo, NAC IV infusion at 0.5 gm hourly and APAP placebo, APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 20 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Brain and Central Nervous System Tumors
Interventions: temozolomide, neoadjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2018
U.S. locations: 38
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more

Conditions: Infantile Spasms
Interventions: Ganaxolone, Placebo; Drug · Other
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 4 Months to 24 Months
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more

Conditions: Mild Traumatic Brain Injury, Distress-based Psychopathology, Chronic Pain
Interventions: Acceptance and Commitment Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Parkinson Disease
Interventions: rTMS; Device
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Huntington Disease
Interventions: Tominersen, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 50 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 15 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dexpramipexole, Dexpramipexole Placebo, Moxifloxacin; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alzheimer Disease
Interventions: Memesto; Device
Lead sponsor: Edgewater Safety Systems, Inc.; Industry
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cerebral Palsy, Hemiplegic Cerebral Palsy, Spastic Hemiplegic Cerebral Palsy, Spastic Hemiparesis, Spastic Hemiplegia
Interventions: active transcranial direct current stimulation, bimanual training; Device · Behavioral
Lead sponsor: Burke Medical Research Institute; Other
Eligibility: 6 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions: OraVescent Fentanyl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 38
States / cities: Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more

Conditions: Alzheimer Disease
Interventions: Bryostatin 1, Placebo; Drug · Other
Lead sponsor: Neurotrope Bioscience, Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Colton, California • San Diego, California • Atlantis, Florida + 16 more

Conditions: Acromegaly
Interventions: Paltusotine; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Diabetes, Cerebrovascular Disease, Age-Associated Decline, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 30 Years to 64 Years
Enrollment: 3,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Sedation, Sleep
Interventions: Continuous bedside video monitoring with AI anatomic landmark tracking for neurologic monitoring; Device
Lead sponsor: Artemis AI Labs; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New York, New York

Conditions: TBI (Traumatic Brain Injury), Concussion, Brain, MTBI - Mild Traumatic Brain Injury, Closed Head Injury
Interventions: EEG Recording, Neurocognitive Tests, Clinician Evaluation, 22-item CSI; Device · Other
Lead sponsor: BrainScope Company, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Detroit, Michigan • Royal Oak, Michigan • Troy, Michigan + 2 more

Conditions: Cyclic Vomiting Syndrome
Interventions: 3mg AZ-010, 1mg AZ010, Staccato Placebo; Combination Product
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Lancaster, California • Los Angeles, California • San Diego, California + 14 more

Conditions: Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions: Valproic acid, Bevacizumab, Radiation therapy; Drug · Radiation
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Years to 21 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 6
States / cities: Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas + 2 more

Conditions: To Determine Efficacy of the Headpod, Cerebral Palsy
Interventions: Headpod; Device
Lead sponsor: Texas Woman's University; Other
Eligibility: 2 Years to 14 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cerebral Ischemia
Interventions: Endovascular autologous mitochondrial transplantation; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma

Nutrition Interventions for Cognitive Enhancement

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology

Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

Memesto Wearable Device for Persons With Dementia

tDCS and Bimanual Therapy for Children With Hemiplegic Cerebral Palsy

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)

Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)

Neonatal Neurological Observation With Video AI

Follow-up of MTBI Patients Discharged from the ED Using Standard Clinical Triage Including BrainScope One

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

Measuring Head Control Change With 2D Video Analysis After Utilization of Headpod in Children With Poor Head Control

Autologous Mitochondrial Transplant for Cerebral Ischemia